# Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

> **NCT04926233** · — · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1371146 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** Tiotropium bromide + Olodaterol
- **DEVICE:** Sp(t)iolto® Respimat®

## Key facts

- **NCT ID:** NCT04926233
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-15
- **Primary completion:** 2020-04-14
- **Final completion:** 2020-04-14
- **Target enrollment:** 1371146 (ACTUAL)
- **Last updated:** 2021-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04926233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04926233, "Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04926233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*